

Key Market Driver In GM1 Gangliosidosis Industry 2025: Advancements In Gene Therapy Fueling Industry Growth

GM1 Gangliosidosis Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 25, 2025
/EINPresswire.com/ -- Updated 2025
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business
Research Company

The Business Research Company

With an impressive CAGR of 11.4%, the GM1 gangliosidosis market size is expected to grow from \$0.51 billion in 2024 to \$0.57 billion in 2025. Various elements have been instrumental in this historic period's growth, such as the rise in GM1 gangliosidosis patients, increased focus on the GM1 gangliosidosis space, the escalating awareness of rare diseases, the popularity of patient-centric research, and the increased emphasis on early intervention.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"

*The Business research
company*

Is the GM1 Gangliosidosis Market Set to Witness
Substantial Growth?

Fueling this substantial growth is the expanding focus on gene therapy and editing, precision medicine, and the adoption of genetic screening programs. These factors are expected to propel the GM1 gangliosidosis market to an estimated \$0.87 billion by 2029 at a CAGR of 11.1%. If the forecast period matches these projections, it will confirm strong advancement in gene-editing technologies, healthcare technology integration, diagnostic techniques, advanced formulations, and genetic therapies.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp>

What Drives The GM1 Gangliosidosis Market Growth?

Advancements in gene therapy, in particular, will serve as a significant growth propellant for the GM1 gangliosidosis market. Gene therapy, a medical treatment that alters or replaces genes within a patient's cells, is being adopted more widely due to progress in genetic research, improved treatment outcomes for previously untreatable conditions, and growing regulatory support for innovative therapies. In this context, gene therapy for GM1 gangliosidosis involves delivering a functional copy of the defective gene to the patient's cells, restoring enzyme activity, and reducing toxic substrate buildup.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report>

Who Are The Key Players In The GM1 [Gangliosidosis Global Market](#)?

Leading the GM1 gangliosidosis market are major companies like Pfizer Inc., Sanofi S.A., Novartis AG, and Takeda Pharmaceutical Company Limited, among others. These industry titans are forming strategic partnerships to maintain their market standing. An example is the partnership between the US-based biotechnology company, GEMMA Biotherapeutics Inc., and Brazil-based health research institution, Oswaldo Cruz Foundation Fiocruz, aimed at developing gene therapies for rare diseases, including GM1 gangliosidosis.

How Is The [GM1 Gangliosidosis Market Segmented](#)?

1 By Disease Type: Type 1 GM1 Gangliosidosis, Type 2 GMT Gangliosidosis, Type 3 GMT Gangliosidosis

2 By Treatment: Anticonvulsants, Bone Marrow Transplantation, Cord-Blood Hematopoietic Stem-Cell Transplantation, Enzyme Replacement, Gene Therapy

3 By End-User: Research Institutes, Hospitals, Other End-Users

Subsegments include:

1 By Type 1 GM1 Gangliosidosis: Classic Infantile Onset, Atypical Infantile Onset

2 By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset, Atypical Juvenile Onset

3 By Type 3 GM1 Gangliosidosis: Classic Adult Onset, Atypical Adult Onset

What Is The Regional Analysis Of GM1 Gangliosidosis Market?

In terms of geography, North America is the market leader due to factors such as higher awareness and adoption of advanced therapies. However, the GM1 gangliosidosis market is globally diverse, spanning Asia-Pacific, Western Europe, Eastern Europe, the Middle East, and Africa.

Browse For More Similar Reports-

Neurostimulation Devices Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report>

Interventional Neurology Devices And Equipment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report>

Neurodegenerative Disorder Therapeutics Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report>

The Business Research Company, a premier destination for market research, provides over 15000+ reports from 27 industries covering 60+ geographies. With 1,500,000 datasets, their wide-ranging research and in-depth insights can assist your company in maintaining its competitive edge in the evolving market.

To learn more about The Business Research Company, visit:

<https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us: info@tbrc.info

Stay connected:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796885750>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.